

Effects of chromium supplementation on selected metabolic responses in resting and exercising horses


I Vervuert^{1,*}, D Cuddeford² and M Coenen³

¹Institute for Animal Nutrition, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, 30173 Hanover, Germany

²Royal (Dick) School of Veterinary Studies, Roslin EH25 9 RG, United Kingdom

³Institute of Animal Nutrition, Nutritional Diseases and Dietities, University of Leipzig, D-04159, Leipzig, Germany

* Corresponding author: Ingrid.Vervuert@tibo-hannover.de



Submitted 13 May 2005; Accepted 5 December 2005

Research Paper

Abstract

Chromium (Cr) is required for insulin function in the control of cellular glucose uptake. Other functions of Cr relate to its effects on growth, lipid metabolism, immune responses and interactions with nucleic acids. This study was conducted to obtain information on the effect of Cr supplementation on the metabolic responses of five exercising Standardbred horses. During the experiment, horses were fed every day for a 21-day period in a randomized order either a yeast product without Cr (control) or with 4.15 or 8.3 mg Cr day⁻¹. Horses were exercised on a treadmill, alternating a work day of low-speed exercise at 5 m s⁻¹ on a 3% incline for 45 min with a rest day. Each horse was adapted over a 21-day period to his or her respective supplementation before undergoing a standardized exercise test (SET). The SET comprised five incremental steps, each of 4 min duration, on a treadmill with a 3% incline; the first step was at 5 m s⁻¹ and was followed with increments of 1 m s⁻¹. Blood samples were taken for lactate, plasma glucose, serum insulin and cortisol estimation before, during and after each SET (30, 120 min and 24 h post-exercise). Blood Cr was estimated 2 h after feeding the control or Cr-enriched yeast (intake 8.3 mg Cr) in two horses. Heart rate was monitored throughout each SET. Blood lactate and plasma glucose peaks were highest at 8 and 9 m s⁻¹ during the SET when 8.3 mg Cr was supplied. Serum insulin levels declined during the SET and there were no treatment-related changes. Twenty-four hours after exercise, plasma glucose and serum cortisol concentrations returned to basal levels or lower. Serum insulin rebounded 30 min after exercise but 24 h later, serum insulin concentrations were below resting levels. During the recovery period, Cr supplementation did not clearly affect metabolic responses. These results suggest that Cr supplementation had no beneficial effect in healthy, exercising horses.

Keywords: Chromium; glucose metabolism; exercise; horse

Introduction

Chromium (Cr) is an essential trace element that is involved in the metabolism of carbohydrates, lipids and proteins by amplifying the activity of insulin^{1,2}. In diabetic humans and rats, Cr supplementation has been shown to increase the cellular uptake of glucose and stimulate insulin metabolism^{1–3}. In that context it is hypothesized that Cr forms a complex between insulin and insulin receptors that facilitates the insulin-tissue interaction¹. Other functions of Cr relate to its effect on growth, lipid metabolism, immune response and interactions with nucleic acids⁴.

Cr is present in several oxidation states, but is most stable in the trivalent state, the predominant form in biological systems⁴. However, the Cr content of foods has not been clearly defined and inorganic Cr³⁺ is poorly absorbed (Table 1). In contrast, Cr⁶⁺ that is derived mainly from industrial exposure is absorbed more readily⁴. The daily dietary Cr intake by humans is generally low, whereas in animals it is considered to be adequate to meet physiological need. There is little retention of Cr and that which is absorbed is excreted primarily via the kidneys⁴. In general, marginal Cr intakes can be

Table 1 The biology of Cr⁴⁻⁷

Feedstuffs (mg kg ⁻¹):	Cereals: 0.1–20.0 Kernels: oat 0.49, barley 0.35, wheat 0.64, rye 0.6 Meat: 0.15 Milk: 0.015 Egg: 0.005–0.02.0 (egg yolk > 20 times) Hay: 0.1–10.0 Water: 0.001–100 Minerals: 60–500
Specification:	Cr ³⁺ : most stable oxidation state, predominant form in biological systems Cr ⁶⁺ : bound to oxygen, strongly oxidizing, toxic properties Cr ⁰ , Cr ²⁺ : no relevance
Absorption:	Passive absorption (small intestine), presumably active transport mechanism, transport of Cr in blood via transferrin Inorganic Cr ³⁺ : <0.5–2.0% (e.g. CrCl ₃) Organic Cr ³⁺ : 25–30% (e.g. high Cr-yeast, CrNic, CrPic)
Excretion:	After absorption: mainly via urinary tract with small losses in faeces, sweat and hair
Storage (mg kg ⁻¹):	Liver: 0.04–1.00 Kidney: 0.05–6.20 Spleen: 0.05–0.30 Hair: 0.20–3.30 Muscle: 0.10–0.20
Requirements:	Humans: 50.0–200 µg day ⁻¹ Horses: no available information
Deficiency:	Decreased sensitivity of peripheral tissues to insulin Impaired protein metabolism
Toxicity:	Cr ³⁺ : very low toxicity Cr ⁶⁺ : allergic dermatitis, skin ulcers, bronchogenic carcinoma by industrial exposure to Cr

compensated by Cr-containing supplements that contain inorganic CrCl₃ or the more available organic forms such as Cr yeast, Cr methionine, Cr nicotinate (CrNic), Cr tripicolinate (CrTri) and Cr picolinate (CrPic).

Studies with humans undergoing strenuous exercise have shown that the urinary excretion of Cr was increased and, as a result, exercise may deplete Cr stores⁸⁻¹⁰. Aside from the compensation of Cr losses, Cr supplementation in athletes would be expected to increase muscle mass by increasing amino acid uptake into cells for incorporation into muscle protein via the potentiating effects of insulin¹⁰. The only reported study with exercising horses suggested that the daily intake of Cr-enriched yeast (5 mg Cr per horse over a 14-day period) had some beneficial effect on glucose metabolism¹¹.

Therefore, the aim of this study was to try to confirm the effects of Cr previously reported in horses and to examine the effect of feeding different levels of Cr-enriched yeast on the metabolism of trained performance horses. We hypothesized that, in healthy exercising horses, Cr supplementation would not improve glucose metabolism.

Material and methods

Animals and diets

Horses

Five trained Standardbred horses—three geldings and two mares—were used in this experiment, with a mean body weight of 412 ± 46 kg, a body condition score of 4¹² and a mean age of 3 ± 2.2 years. The horses were individually housed in box stalls and had free access to a sand paddock 3 h daily. During the experiment the horses were fed a constant basal diet formulated to meet or exceed energy and nutrient requirements according to GEH¹³ (1989) recommendations for the performance horse (5 kg grass hay, 2 kg oats, 0.41 soybean oil, 0.1 kg soybean meal and 0.04 kg NaCl daily). This project was approved by the ethics committee on animal welfare of the Hannover District Government in accordance with German legislation on animal rights and welfare.

Supplementation

In a cross-over design, horses were fed in randomized order each supplement as follows: a yeast product without Cr (= control), a yeast with 4.15 mg Cr (= 4.15 mg Cr, 10.1 ± 1.3 µg kg⁻¹ BW, organic Cr³⁺) or a yeast with 8.3 mg Cr (= 8.3 mg Cr, 20.2 ± 2.4 µg kg⁻¹ BW, organic Cr³⁺). The supplement was given at 700 h and the horses were adapted to each supplement over a 21-day period before undertaking the SET (Fig. 1).

Experimental design

All exercise workouts were performed on a high-speed treadmill (Mustang 2200, Kagra AG, Switzerland). Each horse completed an identical 3-month training programme on the treadmill before the experiment started.

All standardized exercise tests (SET 1–3) started with a warm-up phase in which each horse was exercised at 1.8 ms⁻¹ for 10 min and then at 4.0 ms⁻¹ for 5 min. Each SET continued with five incremental steps, each of 4 min duration. The initial speed was 5 ms⁻¹ and it was increased by 1 ms⁻¹ at each step so that the speed on the last step was 9 ms⁻¹. All exercise workouts were performed on a treadmill with a 3% incline. Exercise tests were started 3 h after the morning feed. All horses completed three SETs during the whole experimental period.

A 3-week training programme (Fig. 1) was initiated before SET 1 and was continued between the SETs.

The routine training programme started with a warm-up period (1.8 ms⁻¹ for 10 min and then 4.0 ms⁻¹ for the next 5 min) and was followed by a low-speed (5 ms⁻¹, fast trot) exercise session for




Fig. 1 Experimental protocol

45 min on a 3% incline with a day of rest after each workday. The whole experiment, including SETs and routine training programme, lasted for 10 weeks.

Sample collection

Two hours before the SET began, an indwelling catheter (1.8 × 2.35 mm/14 G, Braun, Melsungen, Germany) was inserted into the *vena jugularis externa*, connected to a 50 cm-long extension set (Fa. Vygon GmbH, Aachen, Germany) and then sutured into place. The extension set and catheter were flushed with physiological saline after every blood sampling.

For the determination of glucose, blood samples were collected immediately before a SET (at rest, 2 h after feeding), immediately before the first step (warm-up) and after each velocity step during a SET and, finally, after the SET (30 and 120 min and 24 h later).

Blood lactate was measured in samples obtained at rest, immediately before the first step (warm-up) and after each velocity step during a SET. Blood samples for insulin and cortisol estimation were taken before a SET (rest), immediately after the last velocity step of a SET as well as at 30 and 120 min and 24 h after a SET. Blood Cr was only measured in samples from two horses, 2 h after intake of the control or the Cr-enriched yeast (8.3 mg Cr) to test if there was a clear difference in plasma content between different levels of supplementation.

Blood samples were centrifuged (12 000 × *g* for 10 min) within 30 min of collection and serum and plasma were harvested and stored at −20°C for a maximum of 2 months prior to analysis.

Analysis

Lactate analysis of whole blood was performed using a dry chemistry device (Accusport[®], Boehringer, Ingelheim, Germany) and plasma glucose was determined using a glucose hexokinase assay (NobiFlow Glucose-HK[®], Hitado Diagnostic Systems, Mönnesee, Germany, coefficient of variation = 1.8 ± 0.7%).

Serum insulin and cortisol concentrations were measured using RIA (Insulin-RIA, Fa. DPC Biermann

GmbH, Bad Nauheim, Germany, coefficient of variation = 7.9 ± 6.8%; Cortisol RIA according to Klein *et al.*¹⁴, coefficient of variation = 5.8 ± 4.3%). Serum Cr was measured by atomic absorption spectrophotometry (limit of detection: 0.5 µg l⁻¹, Unicam Solar 969, Unicam, Offenbach, Germany).

Heart rate was monitored continuously during SETs by telemetry (monitoring interval of 15 s, Polar[®], Fa. Polar Elektro GmbH, Groß Gerau, Germany).

Statistics

Serum insulin and serum cortisol are presented as means ± SD. Data for blood lactate and plasma glucose are described as means and pooled SD. The mean heart rate data were pooled for each velocity step and data are reported as means ± SD. The coefficient of variation (%) for plasma glucose, serum insulin and serum cortisol was calculated as: 100 × (SD)/(mean value of set). The effects of time and differences between the control and Cr supplementation were tested by analysis of variance for repeated measurements (ANOVA). When *F*-values were significant, further analysis was made using the least significance difference test. Multiple regression was performed to analyse the relationship between serum cortisol and insulin as independent variables and plasma glucose as a dependent variable. Statistical significance was considered at *P* < 0.05.

Results

As expected, heart rate rose significantly during each SET (Table 2). A lower heart rate was recorded at 5 m s⁻¹ for the 4.15 mg Cr intake compared to the control (*P* < 0.05), but at 8 and 9 m s⁻¹, heart rate was lower for the control compared to horses fed Cr.

Exercise-related changes in blood lactate during SETs showed higher blood lactate peaks for Cr supplementation at 8 and 9 m s⁻¹ (Fig. 2).


Table 2 Mean heart rate (beats per min) during SETs for the different treatments ($N=5$, means \pm SD) and at different treadmill speeds

Treatment	n	5 (m s^{-1})	6 (m s^{-1})	7 (m s^{-1})	8 (m s^{-1})	9 (m s^{-1})
Control	5	150 \pm 21 ^{a†}	161 \pm 14 ^{b*}	169 \pm 14 ^{c##}	182 \pm 15 ^{d*}	196 \pm 14 ^{e*}
4.15 mg Cr	5	142 \pm 17 ^{a+}	152 \pm 11 ^{b+}	165 \pm 14 ^{c#}	181 \pm 11 ^{d*}	199 \pm 14 ^{e**}
8.3 mg Cr	5	143 \pm 6 ^{a**}	159 \pm 7 ^{b*}	176 \pm 11 ^{c*}	190 \pm 17 ^{d+}	204 \pm 9 ^{e+}

Mean values in the same row with unlike lower-case superscripts are significantly different ($P < 0.05$); mean values in the same column with unlike symbols are significantly different ($P < 0.05$).


At rest, plasma glucose concentrations were similar for the different treatments (control: $6.0 \pm 0.3 \text{ mmol l}^{-1}$; 4.15 mg Cr: $6.1 \pm 0.06 \text{ mmol l}^{-1}$; 8.3 mg Cr: $6.1 \pm 0.1 \text{ mmol l}^{-1}$). A fall in plasma glucose occurred after the warm-up period and was followed

by a rise during the SETs (time $P < 0.05$; Fig. 3). The highest plasma glucose value was measured at 9 m s^{-1} ($7.9 \pm 0.9 \text{ mmol l}^{-1}$) in horses fed 8.3 mg Cr, whereas the control-fed animals concurrently peaked at up to $6.9 \pm 0.7 \text{ mmol l}^{-1}$ (treatment: $P < 0.05$). During the



Time: $P < 0.05$
 *Treatment 8 m/s: control vs 8.3 mg Cr: $P < 0.05$, and 4.15 mg Cr vs 8.3 mg Cr: $P < 0.05$
 +Treatment 9 m/s: control vs 4.15 mg Cr and 8.3 mg Cr: $P < 0.05$, and 4.15 mg Cr vs 8.3 mg Cr: $P < 0.05$

FIG. 2 Blood lactate concentrations (mmol l^{-1}) before, during and after SETs, for the different treatments ($n=5$, means, pooled SD: 3.8 mmol l^{-1})



Time: $P < 0.05$
 *Treatment 9 m s^{-1} : control vs 8.3 mg Cr: $P < 0.05$

FIG. 3 Plasma glucose concentrations (mmol l^{-1}) before, during and after SETs, and during recovery period for the different treatments ($n=5$, means, pooled SD: 0.95 mmol l^{-1})

recovery period, plasma glucose concentrations fell in all horses irrespective of treatment and 24 h after the SETs, plasma glucose levels were below resting values (time: $P < 0.05$).

Resting serum insulin levels did not vary across the treatments (Table 3). A SET caused a sharp drop in serum insulin, which rebounded 30 min after finishing the SET. At this time, the lowest peak value was measured in horses fed 4.15 mg Cr. During the course of the recovery period, serum insulin concentrations fell again (120 min post-exercise); the fall was most marked in horses fed the control or 8.3 mg Cr. Twenty-four hours after a SET, serum insulin levels were lower than those measured at rest before a SET; there were no treatment-related differences (time: $P < 0.05$). There was no close relationship between serum insulin and plasma glucose values $y = 6.0480 + 0.02179x$, where y , plasma glucose; x , serum insulin ($N = 75$, $r = 0.2$, $\beta = 0.048$, $P > 0.05$).

Slightly lower serum cortisol concentrations (non-significant, Table 3) were measured in horses fed 8.3 mg Cr at rest than for those fed the control or 4.15 mg Cr. Exercise caused an expected increase in serum cortisol with a further rise 30 min after finishing a SET (time $P < 0.05$). At this point, the highest value was measured in control-fed animals; the rise was least in those fed 4.15 mg (treatment $P < 0.05$). During the course of recovery, serum cortisol levels fell and similar basal levels were observed 24 h after exercise for all treatments.

There was a strong relationship between serum cortisol and plasma glucose that was best described by the linear regression equation: $y = 4.907 + 0.0207x$, where y , plasma glucose; x , serum cortisol ($N = 75$, $r = 0.61$, $\beta = 0.614$, $P < 0.001$).

Mean values in the same row with unlike lower-case superscripts are significantly different ($P < 0.05$); mean values in the same column with unlike symbols are significantly different ($P < 0.05$).

The serum Cr content in two horses, 2 h after the consumption of the control yeast or the Cr-enriched yeast, was the same (data not shown).

Discussion

The resting state

The trace element Cr has attracted attention because Cr supplements have been shown to benefit biological functionality and health in both humans and animals.

It has been suggested that Cr decreases insulin levels and improves glucose disposal in Type 2 diabetic and obese humans (Table 4), whereas in healthy humans, Cr supplements did not benefit glucose metabolism.

Furthermore, Cr supplements can benefit production efficiency and immune responses in cattle, poultry and pigs. Cr picolinate supplements increased muscle area and percentage of muscle in the longissimus muscle of growing pigs^{32,33} and litter size in sows³³. Immune function, stimulated by Cr supplementation, was manifested by higher immunoglobulin production, lowered cortisol levels and reduced morbidity in feeder calves³⁴⁻³⁶ and dairy cows³⁷.

The proposed mode of action of Cr is that increases in blood insulin levels stimulate its uptake by insulin-dependent cells, resulting in the binding of Cr to a low-molecular-weight, chromium-binding substance, chromodulin. The binding of four Cr ions to chromodulin enables the link to the insulin-stimulated, insulin receptor, and thereby amplifies insulin signalling³⁸⁻⁴¹. In the present study, Cr supplementation did not affect glucose or insulin concentrations in healthy horses 2 h after a meal. These results were not unexpected as Cr supplementation appears to have its greatest influence in cases of impaired glucose metabolism, such as in diabetes Type 2; normal glucose tolerance is not enhanced^{1-3,42,43}. In humans, the daily dietary Cr intake is often below the recommendations of 50–200 $\mu\text{g day}^{-1}$ in adults ($0.7\text{--}2.8 \mu\text{g kg}^{-1} \text{ BW}$)^{4,8}. Cr deficiency is evidenced by impaired glucose tolerance, a fasting hyperglycaemia, elevated circulating insulin levels and high blood cholesterol and triglyceride concentrations⁴³. As resting glucose metabolism was normal in the current study, Cr intake seemed to be adequate under resting, control conditions. The serum Cr

Table 3 Serum insulin ($\mu\text{U ml}^{-1}$) and cortisol (ng ml^{-1}) concentrations before and after SETs, and during the recovery period for the different treatments ($n = 5$, means \pm SD)

Parameter	Treatment	<i>n</i>	SET		Post-exercise recovery period		
			Before ^z	After	30 min	120 min	24 h
Insulin	Control	5	14.8 \pm 2.9 ^a	1.2 \pm 0.2 ^b	20.6 \pm 7.7 ^{c++}	4.9 \pm 3.3 ^{d++}	2.3 \pm 0.7 ^d
	4.15 mg Cr	5	15.2 \pm 7.1 ^a	1.2 \pm 0.2 ^b	14.7 \pm 12.8 ^{c+}	11.7 \pm 10.0 ^{d+}	3.4 \pm 2.4 ^e
	8.3 mg Cr	5	17.3 \pm 10.0 ^a	1.1 \pm 0.3 ^b	21.7 \pm 6.8 ^{c*}	4.8 \pm 5.2 ^{d*}	4.2 \pm 1.5 ^d
Cortisol	Control	5	45 \pm 22 ^a	89 \pm 22 ^b	110 \pm 31 ^{c*}	62 \pm 13 ^d	35 \pm 19 ^a
	4.15 mg Cr	5	47 \pm 21 ^a	81 \pm 21 ^b	92 \pm 15 ^{c*+}	62 \pm 19 ^d	35 \pm 14 ^a
	8.3 mg Cr	5	37 \pm 12 ^a	83 \pm 12 ^b	99 \pm 22 ^{c+}	61 \pm 11 ^d	30 \pm 6 ^a

Mean values in the same row with unlike lower-case superscripts are significantly different ($P < 0.05$), mean values in the same column with unlike symbols are significantly different ($P < 0.05$).

^z Blood sampling at rest.

Table 4 Effects of Cr supplementation on carbohydrate metabolism in humans^{2,3}

Reference	Study type	Study duration	Dose ($\mu\text{g day}^{-1}$)	Subjects	n	Method	Results	
							Glucose	Insulin
Supplementation of CrCl ₃								
15	OL	2 months	100	D II	12	OGTT	↔	↔
16	DB	4 months	150	D I, II, NonD	14	OGTT	↔	NA
17	DB	4 months	150	D I, II	43	Meal challenge	↔	↔
18	OL	18–133 days	180–3000	D I, II	6	IVGTT, OGTT	↓	NA
19	DB	6 weeks	200	D II	10	OGTT	↔	↓
20	OL	3 months	200	IGT	5	Hyperglycaemic clamp	↔	↔
21	DB	3 months	220	NonD	26	FBG/insulin	↔	↔
22	OL	2 months	500	D II	12	OGTT	↓	↓
23	DB	3 months	600	D I, II	26	FBG	↓	NA
Supplementation CrPic								
24	OL	1–7 days	600	D	3	FBG	↓	NA
25	DB	6 weeks	200	D II	11	FBG	↓	NA
26	DB	2 months	200	D II	30	FBG	↔	NA
27	DB	4 months	200, 1000	D II	180	OGTT	↓	↓
28	DB	2 months	320, 640	GestD	20	OGTT	↓	↓
29	OL	3 months	400	D II	5	Insulin tolerance	↔	↓
30	OL	1–10 months	500	D II	833	Fasting, post-meal	↓	NA
Supplementation Cr yeast								
31	DB	6 months	160	IGT	26	OGTT	↔	↔

OL, open labelled; DB, double-blind; D, diabetic conditions Type 1 or 2; nonD, non-diabetic; GestD, gestation diabetic; OGTT, oral glucose tolerance test; IGT, impaired glucose tolerance; IVGTT, intravenous glucose tolerance test; FBG, fasting blood glucose; NA, not assessed; ↓, decrease; ↔, no effect.

levels were similar in supplemented ($\sim 20.2 \mu\text{g Cr kg}^{-1}$ BW) and non-supplemented horses. In obese women, Cr picolinate supplementation ($\sim 4.5 \mu\text{g Cr kg}^{-1}$ BW) resulted in higher serum Cr levels in the fasted state (Cr: $2.62 \pm 2.7 \mu\text{g l}^{-1}$, placebo: $0.4 \pm 0.41 \mu\text{g l}^{-1}$), at one (Cr: $1.24 \pm 1.3 \mu\text{g l}^{-1}$, placebo: $0.38 \pm 0.45 \mu\text{g l}^{-1}$) and at 2 h (Cr: $1.73 \pm 1.28 \mu\text{g l}^{-1}$, placebo: $0.5 \pm 0.8 \mu\text{g l}^{-1}$) after a meal. However, there was no difference between the placebo and a Cr supplement on blood insulin or glucose levels¹⁰. Despite changes in serum Cr levels after Cr picolinate supplementation, it is generally accepted that circulating Cr does not reflect tissue Cr concentrations⁴³. There is no adequate tool to assess Cr status and, currently, the best method to diagnose Cr deficiency is based on the improvement in glucose tolerance following Cr supplementation¹; the effects of different Cr supplements on post-prandial serum Cr levels have not been established in horses.

The resting glucose and insulin values were similar to those measured by Gentry *et al.*⁴⁴, who found no significant effects of Cr on glucose metabolism in healthy adult mares following intravenous glucose challenge. In contrast, Ott and Kivipelto⁴⁵ showed that Cr supplementation increased the rate at which glucose was metabolized during intravenous glucose tolerance and insulin sensitivity tests in growing horses, with no apparent effects on growth parameters.

The exercise and recovery states

Studies with human athletes have shown that urinary Cr concentrations were increased nearly fivefold 2 h after exercise and, moreover, 24 h urinary Cr losses were about twofold higher on a run day compared to a rest

day^{8–10,46}. These data suggest that Cr needs may be increased during strenuous exercise. Training has an effect in that basal urinary Cr losses seemed to be about 50% lower in trained than in untrained subjects⁸. Urinary Cr losses reflect Cr that has been mobilized and then lost, since Cr is not reabsorbed in the kidneys².

It has been speculated that lower basal urinary Cr losses might be due to a partial depletion of Cr body stores, or that they might reflect an adaptive mechanism to compensate increased Cr losses in exercising human subjects. Aside from the compensation of Cr losses, Cr supplementation in athletes would be expected to increase muscle mass by increasing amino acid uptake into cells for incorporation into muscle protein via the potentiating effects of insulin^{47,48}. However, the effect of Cr supplementation on the body composition of human athletes is equivocal (Table 5); some studies have shown benefits whilst more recent work has failed to demonstrate changes in body composition and glucose metabolism during exercise and training.

In the current study, during exercise, similar insulin concentrations were measured in control and Cr-supplemented horses, but higher glucose peaks occurred at the end of the exercise period in Cr-supplemented horses compared to those fed the control diet. Since serum insulin dropped significantly during exercise, it would seem that Cr did not amplify the effect of insulin and, thus, there was insufficient insulin to stimulate the insulin-dependent receptor and Cr transport into the cells⁴¹. During exercise, and in the early period of recovery, there was an increase in cortisol that would be antagonistic to insulin. This would

Table 5 Effects of supplemental Cr on body composition, minerals and glucose tolerance in exercising humans²

Reference	Subjects	Cr suppl. ($\mu\text{g day}^{-1}$)	Exercise	Duration (weeks)	Method	Results
25	10 males	CrPic: 200	Resistive	5–6	Anthropometry	FFM: \uparrow
25	31 football players	CrPic: 200	Resistive	6	Anthropometry	FFM: \uparrow
49	64 adults	CrPic: 200	Resistive	6	Anthropometry	Circumferences: \uparrow
50	36 football players	CrPic: 200	Resistive	9	Densitometry	No effects
51	95 males and females	CrPic: 200	Aerobic	16	Anthropometry	No effects
52	36 males	CrPic, CrCl ₃ : 170–180	Resistive	8	DXA minerals	DXA: no effects; Iron, copper: \downarrow
47	16 males	CrPic: 200	Resistive	12	Densitometry	No effects
53	43 obese females	CrPic, CrNic: 200	Aerobic	9	Densitometry GT	CrPic without exercise: BW \uparrow CrNic with exercise: BW \downarrow GT: no effects
47	122 adults	CrPic: 400	Variable	9	Densitometry	Weight: \downarrow , fat: \downarrow
54	18 elderly males	CrPic: 1000	Resistive	12	Densitometry	No effects

\uparrow , increase; \downarrow , decrease; FFM, fat-free mass; DXA, dual X-ray absorptiometry; GT, glucose tolerance; BW, body weight.

prevent the entry of glucose into muscle cells and adipose tissue, thereby making it available for tissues of high demand. Exercise-induced changes in cortisol have been frequently reported in horses⁵⁵ and are characterized by a cortisol peak 30 min after finishing strenuous exercise. The close relationship between cortisol and glucose ($r = 0.61$, $P < 0.05$) supports the conclusion that effects of insulin on glucose metabolism ($r = 0.2$, $P > 0.05$) were overridden during exercise and recovery. In stressed calves, reduced cortisol concentrations were measured following Cr supplementation^{34–36}, but the precise mechanism of this effect is unclear. A similar result was obtained in the present investigation; the control-fed group had higher cortisol levels 30 min post-exercise in comparison to horses fed 4.15 mg Cr. However, the higher Cr intake (8.15 mg day^{-1}) did not cause a significant reduction in cortisol and, thus, the effect of Cr appears to be dose independent. The results of the current study contrast with those of Pagan *et al.*¹¹, who measured lowered blood levels of insulin, cortisol and glucose during exercise in trained Thoroughbreds after feeding a Cr-enriched yeast (5 mg Cr day^{-1}). Plasma glucose fell below 4 mmol l^{-1} during high-speed exercise in Pagan's experiment and hypoglycaemia of this nature during exercise may have a negative impact on performance⁵⁶. Furthermore, the decrease in plasma glucose measured by Pagan (even in the control group) was rather surprising in view of the fact that the plasma glucose level in horses performing high-speed exercise normally increases^{57–59}.

The most striking results in the present study were the high lactate and glucose peaks, together with high heart rates measured at the end of exercise in the Cr-supplemented animals. Our results confirm those of Gentry *et al.*⁴⁴, who measured higher lactate levels in Cr-supplemented horses post-exercise.

High heart rates and lactate levels are known to reflect an impaired capacity for exercise in horses. The results obtained in the current study may reflect an interaction between Cr and iron. *In vivo* it has been shown that transferrin is the major transport protein for Cr in blood and, as iron competes with Cr for binding sites, Cr supplementation might inhibit iron binding⁶⁰. In human athletes, a reduction in iron binding to transferrin was measured 8 weeks after the daily supplementation of $\sim 2.8 \mu\text{g Cr kg}^{-1} \text{ BW}$, either as picolinate or chloride⁵². In addition, Cr supplementation significantly affected iron excretion. Compared with a placebo, Cr supplementation reduced urinary iron; a greater reduction was obtained with the Cr picolinate than with the Cr chloride⁵². There were significant decreases in serum iron, ferritin and haemoglobin in rats supplemented with Cr over a 45-day period when compared with control animals⁶¹. In contrast, iron metabolism was unchanged during a 12-week Cr picolinate supplementation ($13.2 \mu\text{g kg}^{-1} \text{ BW}$) in human adults engaged in a resistive training programme⁶². In the present study, it was assumed that a decreased haemoglobin concentration would negatively impact oxygen transport, resulting in higher heart rates and the upregulation of anaerobic metabolic pathways during exercise. It should be emphasized that the level of Cr supplementation in the current study was somewhat higher than that given to humans and the effects on lactate and heart rate seemed to be dose dependent. Unfortunately, there was no estimation of transferrin saturation or haemoglobin during the current work; interactions between Cr and iron warrant further study in exercising performance horses.

In conclusion, Cr supplementation in healthy trained horses elicited no beneficial effects on glucose and insulin metabolism during both rest and exercise. However, Cr supplementation may have beneficial

effects in fat and diabetic horses, and this requires further investigation.

The negative impact of Cr supplementation on heart rate and lactate accumulation during exercise needs further elucidation as there might be an adverse effect of Cr on iron metabolism.

References

- Mertz W (1993). Chromium in human nutrition: a review. *Journal of Nutrition* **123**: 626–633.
- Lukaski HC (1999). Chromium as a supplement. *Annual Reviews of Nutrition* **19**: 279–302.
- Cefalu WT, Wang ZQ, Zhang XH, Baldor LC and Russell JC (2002). Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. *Journal of Nutrition* **132**: 1107–1114.
- McDowell IR (2003). *Minerals in Animal and Human Nutrition*. Amsterdam: Elsevier Science, pp. 497–504.
- Mordenti A, Piva A and Piva G (1997). The European perspective on organic chromium in animal nutrition. In: *Proceedings of Alltech's 13th Annual Symposium*. Nottingham, UK: University of Nottingham Press, pp. 227–240.
- Anke M, Dorn W and Jaritz M (2005). Chrom in der Nahrungskette von pflanze, tier und mensch. *Rekasan Journal* **12**: 59–73.
- Puls R (1994). *Mineral Levels in Animal Health: Diagnostic Data* Clearbrooh, BC Canada: Sherpa International, pp. 72–74.
- Anderson RA, Bryden NA, Polansky MM and Deuster PA (1988). Exercise effects on chromium excretion of trained and untrained men consuming a constant diet. *Journal of Applied Physiology* **64**: 249–252.
- Rubin MA, Miller JP, Ryan AS, Treuth MS, Patterson KY, Pratlley RE, Hurley BF, Veillon C, Moser-Veillon PB and Anderson RA (1998). Acute and chronic resistive exercise increase urinary chromium excretion in man as measured with an enriched chromium stable isotope. *Journal of Nutrition* **128**: 73–78.
- Volpe SL, Huang HW, Larpadisorn K and Lesser I (2001). Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. *Journal of the American College of Nutrition* **20**: 293–306.
- Pagan JD, Rotmensen T and Jackson SG (1995). The effect of chromium supplementation on metabolic response to exercise in Thoroughbred horses. In: *Proceedings of the Equine and Nutrition Symposium*. California, pp. 96–101.
- Henneke DR, Potter GD, Kreider JL and Yeates BF (1983). Relationship between condition score, physical measurements and body fat percentage in mares. *Equine Veterinary Journal* **15**: 371–372.
- Gesellschaft für Ernährungsphysiologie der Haustiere (GEH), (1994). *Empfehlungen zur Energie- und Nährstoffversorgung der Pferde*. Frankfurt (Main): DLG Verlag Frankfurt.
- Klein HJ, Deegen E, Hoogen H and Hoppen HO (1989). Funktionstest der equinen Nebennierenrinde. *Pferdebeilkunde* **5**: 225–230.
- Trow LG, Lewis J, Greenwood RH, Sampson MJ, Self KA, Crews HM and Fairweather-Tait SJ (2000). Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes. *International Journal of Vitamin Nutrition Research* **70**: 14–18.
- Sherman L, Glennon JA, Brech WJ, Klomberg GH and Gordon ES (1968). Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. *Metabolism* **17**: 439–442.
- Rabinowitz MB, Gonick HC, Levin SR and Davidson MB (1983). Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. *Diabetes Care* **6**: 319–327.
- Glinsmann WH and Mertz W (1966). Effect of trivalent chromium on glucose tolerance. *Metabolism* **15**: 510–520.
- Uusitupa MI, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyorala KP, Koivisto PE and Letho JT (1983). Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics. *American Journal of Clinical Nutrition* **38**: 404–410.
- Potter JF, Levin P, Anderson RA, Freiberg JM, Andres R and Elahi D (1985). Glucose metabolism in glucose-intolerant older people during chromium supplementation. *Metabolism* **34**: 199–204.
- Wilson BE and Gandy A (1995). Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects. *Diabetes Research and Clinical Practice* **28**: 179–184.
- Nath R, Minoelia J, Lyall V, Sander S, Kumar V, Kapoor S and Dhar KL (1979). Assessment of chromium metabolism in maturity onset and juvenile diabetes using chromium-51 and therapeutic response of chromium administration on plasma lipids, glucose tolerance and insulin levels. In: D Shapcott and J Hubert (Eds.), *Chromium in Nutrition and Metabolism*. Amsterdam, The Netherlands: Elsevier, pp. 213–222.
- Mossop RT (1983). Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics. *Central African Journal of Medicine* **29**: 80–82.
- Ravina A, Slezak L, Rubal A and Mirsky N (1995). Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. *Journal of Trace Elements in Experimental Medicine* **8**: 183–190.
- Evans GW (1989). The effect of chromium picolinate on insulin controlled parameters in humans. *International Journal of Biosocial and Medicine Research* **11**: 163–180.
- Lee NA and Reasner CA (1994). Beneficial effects of chromium supplementation on serum triglyceride levels in NIDDM. *Diabetes Care* **17**: 1449–1452.
- Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J and Feng J (1997). Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. *Diabetes* **46**: 1786–1791.
- Jovanovic L, Gutierrez M and Peterson CM (1999). Chromium supplementation for women with gestational diabetes mellitus. *Journal of Trace Elements in Experimental Medicine* **12**: 91–97.
- Morris BW, Kouta S, Robinson R, MacNeil S and Heller S (2000). Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus. *Diabetic Medicine* **17**: 684–685.
- Cheng N, Zhu X, Shi H, Wu W, Chi J, Cheng J and Anderson RA (1999). Follow-up survey period in China with type 2 diabetes mellitus consuming supplemental chromium. *Journal of Trace Elements in Experimental Medicine* **12**: 55–60.
- Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rasanen T, Kumpulainen JT and Pyorala K (1992). Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma

- insulin, C-peptide and lipid levels. *British Journal of Nutrition* **68**: 209–216.
- 32 Boleman SL, Boleman SJ, Bidner TD, Southern LL, Ward TL, Pontif JE and Pike MM (1995). Effect of chromium picolinate on growth, body composition, and tissue accretion in pigs. *Journal of Animal Science* **73**: 2033–2042.
- 33 Lindemann MD, Wood CM, Harper AF, Kornegay ET and Anderson RA (1995). Dietary chromium picolinate additions improve gain: feed and carcass characteristics in growing-finishing pigs and increase litter size in reproducing sows. *Journal of Animal Science* **73**: 457–465.
- 34 Chang X and Mowat DN (1992). Supplemental chromium for stressed and growing feeder calves. *Journal of Animal Science* **70**: 559–565.
- 35 Moonsie-Shageer S and Mowat DN (1993). Effect of level of supplemental chromium on performance, serum constituents, and immune status of stressed feeder calves. *Journal of Animal Science* **71**: 232–238.
- 36 Mowat DN, Chang X and Yang WZ (1993). Chelated chromium for stressed feeder calves. *Canadian Journal of Animal Science* **73**: 49–55.
- 37 Burton JL, Mallard BA and Mowat DN (1993). Effects of supplemental chromium on immune responses of periparturient and early lactation dairy cows. *Journal of Animal Science* **71**: 1532–1539.
- 38 Davis CM, Sumrall KH and Vincent JB (1996). A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). *Biochemistry* **35**: 12963–12969.
- 39 Davis CM and Vincent JB (1997). Isolation and characterization of a biologically active chromium oligopeptide from bovine liver. *Archives of Biochemistry and Biophysics* **339**: 335–343.
- 40 Davis CM and Vincent JB (1997). Chromium oligopeptide activates insulin receptor tyrosine kinase activity. *Biochemistry* **36**: 4382–4385.
- 41 Vincent JB (2000). The biochemistry of chromium. *Journal of Nutrition* **130**: 715–718.
- 42 Althuis MD, Jordan NE, Ludington EA and Wittes JT (2002). Glucose and insulin responses to dietary chromium supplements: a meta-analysis. *American Journal of Clinical Nutrition* **76**: 148–155.
- 43 Anderson RA (1994). Stress effects on chromium nutrition of humans and farm animals. In: *Proceedings of Alltech's 10th Annual Symposium*. Nottingham, UK: Nottingham University Press, pp. 267–274.
- 44 Gentry LR, Thompson DL, Fernandez JM, Smith LA, Horohov DW and Leise BS (1999). Effects of chromium tripicolinate supplementation on plasma hormone and metabolite concentrations and immune function in adult mares. *Journal of Equine Veterinary Science* **19**: 259–265.
- 45 Ott EA and Kivipelto J (1999). Influence of chromium tripicolinate on growth and glucose metabolism in yearling horses. *Journal of Animal Science* **77**: 3022–3030.
- 46 Anderson RA, Polansky MM, Bryden NA, Roginski EE, Patterson KY, Veillon C and Glinsmann W (1982). Urinary chromium excretion of human subjects: effects of chromium supplementation and glucose loading. *American Journal of Clinical Nutrition* **36**: 1184–1193.
- 47 Hallmark MA, Reynolds TH, DeSouza CA, Dotson CO, Anderson RA and Rogers MA (1996). Effects of chromium and resistive training on muscle strength and body composition. *Medicine and Science in Sports and Exercise* **28**: 139–144.
- 48 Kaats GR, Blum K, Fisher JA and Adelman JA (1996). Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo controlled study. *Current Therapeutic Research* **57**: 747–756.
- 49 Hasten DL, Rome EP, Franks BD and Hegsted M (1992). Effects of chromium picolinate on beginning weight training students. *International Journal of Sport and Nutrition* **2**: 343–350.
- 50 Clancy SP, Clarkson PM, DeCheke ME, Nosaka K, Freedson PS, Cunningham JJ and Valentine B (1994). Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. *International Journal of Sport and Nutrition* **4**: 142–153.
- 51 Trent LK and Thieding-Cancel D (1995). Effects of chromium picolinate on body composition. *Journal of Sports Medicine and Physical Fitness* **35**: 273–280.
- 52 Lukaski HC, Bolonchuk WW, Siders WA and Milne DB (1996). Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. *American Journal of Clinical Nutrition* **63**: 954–965.
- 53 Grant KE, Chandler RM, Castle AL and Ivy JL (1997). Chromium and exercise training: effect on obese women. *Medicine and Science in Sports and Exercise* **29**: 992–998.
- 54 Campbell WW, Joseph LJ, Davey SL, Cyr-Campbell D, Anderson RA and Evans WJ (1999). Effects of resistance training and chromium picolinate on body composition and skeletal muscle in older men. *Journal of Applied Physiology* **86**: 29–39.
- 55 Desmecht D, Linden A, Amory H, Art T and Lekeux P (1996). Relationship of plasma lactate production to cortisol release following completion of different types of sporting events in horses. *Veterinary Research Communications* **20**: 371–379.
- 56 Lawrence LM, Williams J, Soderholm LV, Roberts AM and Hintz HF (1995). Effect of feeding state on the response of horses to repeated bouts of intense exercise. *Equine Veterinary Journal* **27**: 27–30.
- 57 Judson GH, Frauenfelder HC and Mooney (1983). Biochemical changes in Thoroughbred racehorses following submaximal and maximal exercise. In: DH Snow, SGB Perrsson & RJ Rose (eds), *Equine Exercise Physiology*. Cambridge: Granta Editions, pp. 408–415.
- 58 Snow DH, Mason DK, Ricketts SW and Douglas TA (1983). Post-race blood biochemistry in Thoroughbreds. In: DH Snow, SGB Perrsson & RJ Rose (eds), *Equine Exercise Physiology*. Cambridge: Granta Editions (pp. 389–407).
- 59 Lawrence LM (1990). Nutrition and fuel utilization in the athletic horse. *Veterinary Clinics of North America, Equine Practice* **6**: 393–417.
- 60 Moshtaghie AA, Ani M and Bazrafshan MR (1992). Comparative binding study of aluminum and chromium to human transferrin. Effect of iron. *Journal of Trace Elements in Experimental Medicine* **32**: 39–46.
- 61 Ani M and Moshtaghie AA (1992). The effect of chromium on parameters related to iron metabolism. *Journal of Trace Elements in Experimental Medicine* **32**: 57–64.
- 62 Campbell WW, Beard JL, Joseph LJ, Davey SL and Evans WJ (1997). Chromium picolinate supplementation and resistive training by older men: effects on iron-status and hematologic indexes. *American Journal of Clinical Nutrition* **66**: 944–949.